What is Cytiva?
Headquartered in Stevenage, Hertfordshire, Cytiva operates at the intersection of advanced research and development. The firm is positioned as a specialized entity within the life sciences sector, focusing on the translation of complex scientific discoveries into viable commercial solutions. With a lean operational structure, the company leverages its proximity to world-class academic institutions to drive innovation in therapeutic development and biotechnology. Its market position is defined by its ability to bridge the gap between academic research and industrial application, serving as a critical node in the UK's broader biotech value chain.
How much funding has Cytiva raised?
Cytiva has raised a total of $4.2M across 2 funding rounds:
Angel/Seed
$1.4M
Series A
$2.8M
Angel/Seed (2014): $1.4M with participation from UCL Business PLC, S.R.One Ltd, and Imperial Innovations Group plc
Series A (2015): $2.8M led by Imperial Innovations, SR One, and UCL Business
Key Investors in Cytiva
Imperial Innovations
A premier technology commercialization firm linked to Imperial College London, focusing on translating world-class engineering and medical research into commercial ventures.
SR One
A transatlantic biotechnology venture capital firm that specializes in early and growth-stage life sciences companies, providing strategic support for novel therapeutic development.
UCL Business
The commercialization arm of University College London, dedicated to bringing pioneering academic research and healthcare innovations to the global market.
What's next for Cytiva?
Looking ahead, the infusion of capital positions Cytiva to accelerate its pipeline development and potentially expand its footprint within the global life sciences market. The strategic focus will likely remain on optimizing its R&D workflows and deepening its collaborative ties with academic partners to ensure a steady stream of intellectual property. As the company matures, the emphasis will shift toward scaling its operational capacity to meet the increasing demand for novel therapeutics, while simultaneously navigating the regulatory and commercial challenges inherent in the biotechnology industry. Future growth will be contingent upon the successful execution of its current development roadmap and the continued support of its institutional backers.
See full Cytiva company page
